Pneumeric has an exclusive patent license with Mayo Clinic to commercialize the Capnospot®.  The Company has achieved initial traction in the pre-hospital space (Fire/Rescue/EMS) using a distributor and direct-to-consumer model.  The shelf life of two years presents a compelling recurring revenue component.  We believe the Capnospot® will become the new standard of care over time. 

We estimate the total addressable market (TAM) to be in excess of 5 million units worldwide. The primary market for Capnospot® is providers of pre-hospital medical services in the U.S. and EU.  This includes both military and civilian markets. Civilian markets, inclusive of all EMS providers, represent the initial market.  It is assumed that 85% of revenue will be generated by wholesale orders @ $15-20 per unit and 15% will be direct sales @ $25-35 per unit.

Customer segments include:

1) Indirect wholesale channel to both Civilian (EMS/Fire/Rescue) and Military (DoD);

2) Direct retail channel to first-responders;

3) Strategic partnerships (e.g., licensing or OEM opportunities for inclusion in existing trauma and/or chest tube kits)

The primary distribution channels for the Capnospot® will be established medical device distributors. In the civilian market, these include (not limited to) Bound Tree, Rescue Essentials and North American Rescue.  Military distributors include ADS and Maclean Health. Additional distribution opportunities exist with OEM trauma kit suppliers. Pneumeric will also offer a direct sales channel for the Capnospot®.

There is no known clinical methodology for rapid detection of needle efficacy and there are no direct competitors.

Innovation is this space has been various adaptations of spring-loaded angiocatheters that do not present a competitive threat, but potential licensing opportunities.

The Capnospot® is a novel Class I medical device.

Revenue will be realized from product sales through several channels, including:

 

1.        Direct sales to EMS, Fire, Police, and Individual Providers.

2.       Distribution to Municipalities, EMS, Fire, Police. 

3.       Distribution to the Federal Government, Military/DoD.

4.       Licensing or OEM opportunities for inclusion in existing trauma and/or chest tube kits. 

 

The distributor model is fairly standard for medical devices and is essential to dissemination of the Capnospot®.  We have several distributor agreements in the US, both civilian and military, to place product and ultimately build adoption since granted regulatory clearance in March 2023.

 

Potential licensing arrangements are numerous and would to permit a manufacturer of kits or catheters (needles) to use the Capnospot® as an adjunct for their own device or product. It is worth noting the significant recurring revenue component with each sale as the shelf life of the Capnospot® is two years.